A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101-

  • Takashi KasaiEmail author
  • Kiyoshi Mori
  • Kazuma Kishi
  • Takayuki Kaburagi
  • Yukio Hosomi
  • Hisao Imai
  • Yutaka Yamada
  • Makiko Yomota
  • Syuhei Moriguchi
  • Masahiro Seike
  • Koichi Minato
  • Akihiko Gemma
  • for The Tokyo Cooperative Oncology Group
Original Article



Combination carboplatin and S-1 is active in the treatment of non-small cell lung cancer (NSCLC). However, data on this combination for elderly patients with NSCLC are insufficient.


Eligibility criteria were no prior chemotherapy, Stage IIIB or IV NSCLC, performance status 0–1, age ≥ 75 years, and adequate hematological, hepatic, and renal functions. Carboplatin was administered on day 1 and S-1 was administered orally, twice a day, between days 1 and 14, repeated every 3 weeks. In phase I, the primary purpose was determination of the recommended dose. Starting doses of carboplatin and S-1 were area under the curve (AUC) of 4 and 80 mg/m2/day, respectively. In the extension study, the effects and tolerability of this combination therapy of recommended dose were confirmed.


A total of 10 patients were entered into phase I and 14 patients were entered into the extension study. The recommended doses for this drug combination are AUC 5 for carboplatin and 80 mg/m2/day every 3 weeks for S-1. With carboplatin and S-1 combination therapy at the recommended dose, the response rate was 30.0% [95% confidence interval (CI) 12–54%] and the disease control rate was 90.0% (95% CI 68–99%). Thrombocytopenia and neutropenia were major adverse events.


The recommended doses for this combination therapy are carboplatin AUC 5 and S-1 80 mg/m2/day every 3 weeks, and this combination is effective with tolerable toxicities for advanced NSCLC patients ≥ 75 years old.


Phase I study Extension study S-1 Carboplatin Elderly patients Non-small cell lung cancer 



This study was supported by The Tokyo Cooperative Oncology Group.

Compliance with ethical standards

Conflict of interest

No author has any conflict of interest.


  1. 1.
    Siegel RS, Miller KD, Jemel A (2016) Cancer statistics 2016. CA Cancer J Clin 66:7–30CrossRefGoogle Scholar
  2. 2.
    Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866–1872CrossRefGoogle Scholar
  3. 3.
    Souquet PJ, Chauvin F, Boissel JP et al (1993) Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342:19–21CrossRefGoogle Scholar
  4. 4.
    Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899–909CrossRefGoogle Scholar
  5. 5.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129–2139CrossRefGoogle Scholar
  6. 6.
    Yang JC, Sequist LV, Geater SL et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16(7):830–838CrossRefGoogle Scholar
  7. 7.
    Maemondo M, Minegishi Y, Inoue A et al (2012) First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol 7(9):1417–1422CrossRefGoogle Scholar
  8. 8.
    Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167–2177CrossRefGoogle Scholar
  9. 9.
    Hida T, Nokihara H, Kondo M et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390(10089):29–39CrossRefGoogle Scholar
  10. 10.
    Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866–2874CrossRefGoogle Scholar
  11. 11.
    Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123–135CrossRefGoogle Scholar
  12. 12.
    Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627–1639CrossRefGoogle Scholar
  13. 13.
    Davidoff AJ, Tang M, Seal B et al (2010) Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28:2191–2197CrossRefGoogle Scholar
  14. 14.
    The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72CrossRefGoogle Scholar
  15. 15.
    Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372CrossRefGoogle Scholar
  16. 16.
    Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24:3657–3663CrossRefGoogle Scholar
  17. 17.
    Quoix E, Zalcman G, Oster JP et al (2011) Intergroupe Francophone de Cancérologie Thoracique: carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomized, phase 3 trial. Lancet 378:1079–1088CrossRefGoogle Scholar
  18. 18.
    Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557CrossRefGoogle Scholar
  19. 19.
    Kasai T, Nakamura Y, Fukuda M et al (2016) A phase II study of S-1 for previously untreated elderly patients with advanced non-small cell lung cancer. Chemotherapy 61(2):93–98CrossRefGoogle Scholar
  20. 20.
    Goto H, Okano Y, Machida H et al (2018) Phase II study of tailored S-1 monotherapy with a 1-week interval after a 2-week dosing period in elderly patients with advanced non-small cell lung cancer. Respir Investig 56(1):80–86CrossRefGoogle Scholar
  21. 21.
    Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28(36):5240–5246CrossRefGoogle Scholar
  22. 22.
    Abe T, Takeda K, Ohe Y et al (2015) Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: The Intergroup Trial JCOG0803/WJOG4307L. J Clin Oncol 33:575–581CrossRefGoogle Scholar
  23. 23.
    Nokihara H, Lu S, Mok TSK et al (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28(11):2698–2706CrossRefGoogle Scholar
  24. 24.
    Kuyama S, Ochi N, Bessho A et al (2017) A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: the Okayama Lung Cancer Study Group Trial 1202. Lung Cancer 112:188–194CrossRefGoogle Scholar
  25. 25.
    Okamoto I, Nokihara H, Yoh K et al (2019) Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). American Society of Clinical Oncology Annual Meeting. Abstract 9031 Google Scholar
  26. 26.
    Mok TSK, Wu YL, Kudaba I, for the KEYNOTE-042 Investigators, et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase 3 trial. Lancet 393(10183):1819–1830. CrossRefGoogle Scholar
  27. 27.
    Socinski MA, Jotte RM, Cappuzzo F, IMpower150 Study Group et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378(24):2288–2301CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2020

Authors and Affiliations

  • Takashi Kasai
    • 1
    Email author
  • Kiyoshi Mori
    • 2
  • Kazuma Kishi
    • 3
  • Takayuki Kaburagi
    • 4
  • Yukio Hosomi
    • 5
  • Hisao Imai
    • 6
  • Yutaka Yamada
    • 4
  • Makiko Yomota
    • 5
  • Syuhei Moriguchi
    • 7
  • Masahiro Seike
    • 8
  • Koichi Minato
    • 6
  • Akihiko Gemma
    • 8
  • for The Tokyo Cooperative Oncology Group
  1. 1.Division of Thoracic Oncology, Department of Medical OncologyTochigi Cancer CenterUtsunomiyaJapan
  2. 2.Division of Thoracic Oncology, Department of Thoracic DiseasesTsuboi Cancer Center HospitalFukushimaJapan
  3. 3.Department of Respiratory MedicineToho University Omori Medical CenterTokyoJapan
  4. 4.Division of Respiratory MedicineIbaraki Prefectural Central Hospital and Regional Cancer CenterIbarakiJapan
  5. 5.Division of Respiratory MedicineTokyo Metropolitan Cancer and Infectious Diseases Center Komagome HospitalTokyoJapan
  6. 6.Division of Thoracic OncologyGunma Cancer CenterGunmaJapan
  7. 7.Department of Respiratory Medicine, Respiratory CenterToranomon HospitalTokyoJapan
  8. 8.Department of Pulmonary Medicine, Oncology and Infectious Disease, Graduate School of MedicineNippon Medical SchoolTokyoJapan

Personalised recommendations